SOHO 2023 Scientific Program

The eleventh annual meeting of the Society of Hematologic Oncology (SOHO 2023) will be held on September 6-9, 2023 as a hybrid event (attendance in-person plus virtual access).

This 3.5-day program will focus on state-of-the-art approaches and will include a variety of educational formats including: general sessions, meet-the-professor sessions, breakfast with the expert, debates and plenary sessions.

Below you will find the SOHO 2023 Program-at-a-Glance and detailed program information listed by day. Note that SOHO members have early access to session selections. To sign-up for FREE SOHO membership, go to soho.click/join to receive a 40% discount on registration rates.

SOHO 2023 Program at a Glance

Program-at-a-Glance

SOHO 2023 Detailed Program

Select a tab to view the SOHO 2023 detailed program by day.

Wednesday, September 6, 2023

Meet-the-Professor I
MTP I: AML
MTP II: ALL
MTP III: HL
MTP IV: NHL
MTP V: CML
MTP VI: MPN
MTP VII: MDS
MTP VIII: MM
MTP IX: CLL
MTP X: CT

MTP I Details
Meet-the-Professor II
MTP XI: AML
MTP XII: ALL
MTP XIII: Lymphoma 1
MTP XIV: Lymphoma 2
MTP XV: CML
MTP XVI: MPN
MTP XVII: MDS
MTP XVIII: MM
MTP XIX: CLL
MTP XX: CT

MTP II Details
7:00 AM–
7:45 AM
8:00 AM–
8:45 AM
Session I: Acute Lymphoblastic Leukemia
Chairs: Selina Luger & Josep-Maria Ribera
  • Welcome and Opening Remarks
    Jennifer  Brown, MD, PhD  |  President, SOHO
  • ALL with Myeloid Mutations: What Does
    It Mean?
    Caner Saygin, MD  |  University of Chicago, Chicago, Illinois, USA
  • Ph+ ALL – Novel Therapies
    Elias Jabbour, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Menin Inhibition for KMT2A
    Rearranged ALL
    Eytan  Stein, MD  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA
  • Approach to Ph-Like ALL
    Ilaria Iacobucci, PhD  |  St. Jude Children's Hospital, Memphis, Tennessee, USA
  • CNS Prophylaxis in ALL
    Partow Kebriaei, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Sequencing Immunotherapies in Adults
    with ALL
    Bijal Shah, MD  |  H. Lee Moffitt Cancer Center, Tampa, Florida, USA
  • Role of Transplant in the Era of CAR T Cells
    Jae Park, MD  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA
  • Oral Abstract  |  ALL
    TBA

9:00 AM–
11:26 AM
Lunch Sessions: Independent Satellite Symposia
  • ISS Lunch Session I
    TBA
  • ISS Lunch Session II
    TBA
11:41 AM–
12:41 PM
Plenary Session I
Chair: Sagar Lonial
  • Acute Lymphoblastic Leukemia
    Hagop Kantarjian, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
    Recipient of the Emil J Freireich Distinguished Pioneer Award
12:56 PM–
1:16 PM
Session II: Myelodysplastic Neoplasms
Chairs: Guillermo Garcia-Manero & Amy DeZern
  • Update on the Biology of MDS
    Simona Colla, PhD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Update on Classifications and
    Prognostic Models
    Joseph D Khoury, MD  |  University of Nebraska, Omaha, Nebraska, USA
  • Update on CHIP and CCUS
    Lachelle D Weeks, MD, PhD  |  Dana-Farber Cancer Inst, Boston, Massachusetts, USA
  • Update on Treatment of Lower Risk MDS
    Uwe Platzbecker, MD  |  Leipzig University Hospital, Leipzig, Germany
  • Update on Treatment of Higher Risk MDS
    Rami Komrokji, MD  |  H. Lee Moffitt Cancer Center, Tampa, Florida, USA
  • Oral Abstract  |  MDS
    TBA
1:16 PM–
2:56 PM
Session III: Acute Myeloid Leukemia
Chairs: Daniel Pollyea & Farhad Ravandi
  • What is the Future of Menin Inhibitors in AML?
    Ghayas C Issa, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Is Acute Monomyelocytic Leukemia a Separate Entity?
    Daniel Pollyea, MD, MS  |  University of Colorado, Denver, Colorado, USA
  • What is the Role of Quizartinib in the Current Landscape of AML Therapy?
    Harry P Erba, MD, PhD  |  Duke University,  Durham, North Carolina, USA
  • Triplet Regimens in AML: Beyond Azacytidine Plus Venetoclax
    Courtney DiNardo, MD, MSCE  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Post-Transplant Maintenance Therapy
    Betul Oran, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • DEBATE: No Therapy vs Achieving Best Response Prior to Transplant
    Prior Therapy Is Not Needed for Transplanting Patients With Relapsed or Refractory AML
    Johannes Schetelig, MD  |  Univ of Dresden, Dresden, Germany 
    Achieving Best Response Is Desirable Prior to Allogeneic Stem Cell Transplant
    Roland Walter, MD, PhD  |  Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
  • Familial Predisposition to AML: Prevalence and Implications for Management
    Lucy A Godley, MD, PhD  |  Northwestern University, Chicago, Illinois, USA
  • Oral Abstract  |  AML
    TBA

3:26 PM–
6:00 PM
Poster Session & Awards Reception
  • Poster Viewing & Discussion
  • Awards Ceremony
6:00 PM–
7:30 PM
Dinner Session: Independent Satellite Symposium III
  • ISS Dinner Session III
    TBA
7:30 PM–
8:30 PM

Thursday, September 7, 2023

Breakfast Sessions: ISS, IES and Expert Breakfast
  • ISS IV Breakfast Session 
    TBA



  • IES Breakfast Session (non-accredited)
    TBA

    This activity is sponsored by GlaxoSmithKline

  • Breakfast with the Expert I
    New Options for TP53 Mutated AML
    Naval Daver, MD  |  MD Anderson Cancer Ctr
6:45 AM–
7:45 AM
Dessert Session: Industry Expert Sessions (non-accredited)
  • IES III Dessert Session
    TBA
    This activity is sponsored by Bristol Myers Squibb
  • IES IV Dessert Session
    TBA
    This activity is sponsored by Genentech
Session IV: Chronic Myeloid Leukemia
Chairs: Nick Cross & Simona Soverini
  • High Resolution Mutation Testing and Other Non-BCR-ABL Mutations: The Significance to Decision in the Routine Patient
    David Ross, MBBS, PhD, FRACP, FRCPA  |  Royal Adelaide Hospital and Institute, Adelaide, Australia
  • Epigenetic Dysregulation of CML
    Sin Tiong Ong, MD  |  Duke NUS Medical School, Singapore
  • Rational Choice of TKI
    Michael Deininger, MD, PhD  |  Versiti Blood Research Inst, Milwaukee, Wisconsin, USA
  • Cost Benefit Role of TKI Choice 
    Hagop Kantarjian, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • The New ELN Molecular Guidelines
    Nick Cross, MA, PhD, FRCPath  |  University of Southampton, Salisbury, United Kingdom
  • Oral Abstract  |  CML
    TBA


7:39 PM–
8:39 PM
8:00 AM–
9:40 AM
Session V: Myeloproliferative Neoplasms
Chairs: Francesco Passamonti & Olatoyosi Odenike
  • Modern Prognostication in Classic MPNs
    Francesco Passamonti, MD  |  University of Insubria, Varese, Italy
  • Managing Accelerated & Blast Phase MPN
    Olatoyosi Odenike, MD  |  University of Chicago, Chicago, Illinois, USA
  • Choosing and Properly Using a JAK Inhibitor in Myelofibrosis
    Anthony M Hunter, MD  |  Winship Cancer Institute, Atlanta, Georgia, USA
  • Addressing Anemia in Myelofibrosis
    Stephen T Oh, MD, PhD  |  Washington University, St. Louis, Missouri
  • Novel Non-JAK Inhibitor Therapies for Myelofibrosis
    John Mascarenhas, MD  |  Mount Sinai Medical Center, New York, New York, USA
  • Oral Abstract  |  MPN
    TBA

10:10 AM–
11:50 AM
Lunch Sessions: Independent Expert Sessions (non-accredited)
  • IES I Lunch Session

    TBA
    This activity is sponsored by Bristol Myers Squibb
  • IES II Lunch Session 
    TBA
    This activity is sponsored by Incyte

12:05 PM–
1:05 PM
Plenary Session II
Chair: Hagop Kantarjian
  • Chronic Myeloid Leukemia
    Jorge Cortés, MD  |  Augusta University, Augusta, Georgia, USA
    Recipient of the Michael J. Keating Outstanding Achievement Award
1:20 PM–
1:40 PM
Session VI: Multiple Myeloma
Chairs: Tom Martin & Krina Patel
  • Frontline Treatment for High-Risk: Personalized?
    Saad Z Usmani, MD, MBA, FACP  |  Memorial Sloan Kettering, New York, New York, USA
  • Debate: Watch and Wait vs Treatment for Smoldering Multiple Myeloma
    Smoldering MM: Time to Watch and Wait
    Angela Dispenzieri, MD  |  Mayo Clinic Rochester, Rochester, Minnesota, USA
    Smoldering MM: Time to Treat – Personalized?
    Sagar Lonial, MD, FACP  |  Winship Cancer Institute, Atlanta, Georgia, USA
  • Treatment of Frail MM Patients—Personalized Care
    Elizabeth K. O'Donnell, MD  |  Dana-Farber Cancer Inst, Boston, Massachusetts, USA
  • BCMA/GPRC5D/FcRH5 | CARs/BsAbs—How to Choose
    Ajai Chari, MD  |  Mount Sinai Hospital, New York, New York, USA
  • CAR/BsAb Toxicity: Prevention, Treatment and Surveillance
    Noopur Raje, MD  |  Massachusetts General Hospital, Boston, Massachusetts, USA
  • Next Generation Therapeutics: Degraders and Targeted Therapy | Where Will They Fit? Personalized Therapy in MM
    Ajay K Nooka, MD, MPH, FACP  |  Winship Cancer Institute, Atlanta, Georgia, USA
  • Oral Abstract  |  MM
    TBA
1:40 PM–
3:56 PM
Session VII: Chronic Lymphoctic Leukemia
Chairs: Carol Moreno & Paolo Ghia
  • Clinical Significance of MBL
    Sameer A Parikh, MBBS  |  Mayo Clinic, Rochester, Minnesota, USA
  • Is FD Therapy the New SOC in FL CLL?
    Alessandra Ferrajoli, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Debate: Stop vs Continue VenG: MRD+ at 1 Year of VenG
    MRD+ at 1 Year of VenG: Stop Therapy
    Othman Al-Sawaf, MD  |  University Hospital of Cologne, Cologne, Germany
    MRD+ at 1 Year of VenG: Continue VenG
    Nicole Lamanna, MD  |  Herbert Irving Comp Cancer Ctr, New York, New York, USA
  • How We Developed a Curative Therapy for CLL and Stopped Using It
    John Seymour, MBBS, FRACP, PhD  |  Peter MacCallum Cancer Centre, Melbourne, Australia
  • How Biologic Markers Impact Outcomes With Novel Therapy
    Talha Munir, MD  |  St. James’s Hospital, Leeds, United Kingdom
  • Oral Abstract  |  CLL
    TBA
4:26 PM–
6:24 PM
Dinner Session: Independent Satellite Symposia
  • ISS Dinner Session V
    TBA
  • ISS Dinner Session VI
    TBA
6:34 PM–
7:34 PM

Friday, September 8, 2023

Breakfast Sessions: ISS and Expert Breakfast
  • ISS VII Breakfast Session 
    TBA


  • Breakfast with the Expert II
    CML and Pregnancy
    Elisabetta Abruzzese, MD, PhD  |  S. Eugenio University Hospital, Rome, Italy
6:45 AM–
7:45 AM
Dinner Session: Industry Expert Sessions (non-accredited)
  • IES Dinner  Session VII
    TBA
    This activity is sponsored by Genentech
  • IES Dinner Session VIII
    TBA
    This activity is sponsored by Genentech
Session VIII: T-Cell Lymphoma
Chairs: Barbara Pro & Jasmine Zain
  • New Insights Into the Pathogenesis of T-Cell Lymphoma and How This May Guide Treatment
    Laurence de Leval, MD, PhD  |  University Hospital of Lausanne, Lausanne, Switzerland
  • Tailoring Therapy In PTCL
    Jasmine M Zain, MD  |  City of Hope, Duarte, California, USA
  • Managing Rare T-Cell Lymphoma Subtypes
    Barbara Pro, MD  |  Columbia University, New York, New York, USA
  • Novel Targeted Agents in T-Cell Lymphoma
    Pier Luigi Zinzani, MD, PhD  |  University of Bologna, Bologna, Italy
  • A Multidisciplinary Approach to the Management of Mycosis Fungoides
    Christiane Querfeld, MD, PhD  |  City of Hope Cancer Center, Duarte, California, USA
  • Oral Abstract  |  TCL
    TBA


7:13 PM–
8:13 PM
8:00 AM–
9:40 AM
Session IX: Indolent B-Cell Lymphoma
Chairs: Brad Kahl & Emanuele Zucca
  • Treatment of Follicular Lymphoma, What is the New Order?
    Brad S Kahl, MD  |  Washington University Medical School, St. Louis, Missouri, USA
  • Bispecific Antibodies or CAR T-Cells for Indolent NHL?
    Caron A Jacobson, MD, MMSc  |  Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Novel Combinations in Indolent Lymphoma
    Paolo Strati, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Treatment Options for Marginal Zone Lymphoma
    Emanuele Zucca, MD  |  Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
  • Oral Abstract  |  IBCL
    TBA



10:10 AM–
11:32 AM
Lunch Sessions: Independent Satellite Symposia
  • ISS VIII Lunch Session 
    TBA
  • ISS IX Lunch Session 
    TBA
11:47 AM–
12:47 PM
Plenary Session III
Chair: Susan O'Brien
  • Emerging BCL 2 Inhibitors
    Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD   |  Royal Melbourne Hospital, Melbourne, Australia
1:02 PM–
1:22 PM
Session X: Aggressive B-Cell Lymphoma
Chairs: Laurie Sehn & Christopher Flowers
  • Incorporating Novel Agents in Frontline DLBCL
    Laurie Sehn, MD, MPH  |  BC Cancer Agency, Vancouver, Canada
  • The New Algorithm for Second-Line LBCL
    Jason Westin, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • The Emergence of Bispecific Antibodies in Aggressive B-Cell Lymphoma
    Martin Hutchings, MD, PhD  |  Copenhagen University Hospital, Copenhagen, Denmark
  • Optimizing the Use of Novel Agents in Relapsed/Refractory DLBCL
    Christopher Flowers, MD, MS  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Treatment Options for Primary Mediastinal B-Cell Lymphoma
    Kieron Dunleavy, MD  |  Georgetown University, Washington, DC, USA
  • The Treatment of Primary and Secondary CNS Lymphoma
    Kate Cwynarski, MBBS, PhD, FRCP, FRCPath  |  University College London, London, United Kingdom
  • Oral Abstract  |  ABCL
    TBA
1:22 PM–
3:20 PM
Session XI: Mantle Cell Lymphoma
Chairs: Anita Kumar & Tycel Phillips
  • Is Stem Cell Transplantation Still Necessary in Frontline Mantle Cell Lymphoma?
    Timothy Fenske, MD, MS  |  Froedtert Hospital, Milwaukee, Wisconsin, USA
  • What is High Risk Mantle Cell Lymphoma and How Should We Treat It?
    Anita Kumar, MD   |  Memorial Sloan Kettering, New York, New York, USA
  • CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma
    Tycel J Phillips, MD  |  City of Hope Cancer Center, Duarte, California, USA
  • Emerging Novel Agents in Mantle Cell Lymphoma
    Kami J Maddocks, MD  |  Ohio State University, Columbus, Ohio, USA
  • Oral Abstract  |  MCL
    TBA
3:50 PM–
5:12 PM
Session XII: Hodgkin Lymphoma
Chairs: Catherine Diefenbach & Jonathan Friedberg
  • Risk-Based Treatment of Hodgkin Lymphoma in the Era of Novel Therapies
    Catherine S Diefenbach, MD  |  NYU Langone Health, New York, New York, USA
  • Treatment of HL in Older Patients
    Jonathan W Friedberg, MD, MMSc  |  University of Rochester Medical Center, Rochester, USA
  • Oral Abstract  |  HL
    TBA



5:12 PM–
5:58 PM
Hors d'Oeuvres and Cocktails: Industry Expert Sessions (non-accredited)
  • IES Hors d'Oeuvres Session V
    TBA
    This activity is sponsored by Pfizer
  • IES Hors d'Oeuvres Session VI
    TBA
    This activity is sponsored by AstraZeneca
6:08 PM–
7:08 PM
Dessert Session: Industry Expert Session (non-accredited)
  • IES Dessert Session IX
    TBA
    This activity is sponsored by Gilead
8:18 PM–
9:18 PM

Saturday, September 9, 2023

Breakfast Sessions: ISS and Expert Breakfast
  • ISS X Breakfast Session 
    TBA

  • Harnessing the Immune System in Patients With Lymphoma
    Stephen M Ansell, MD, PhD  |  Mayo Clinic, Rochester
6:45 AM–
7:45 AM
Session XIII: Cellular Therapy
Chairs: Krina Patel & Hugo Fernandez
  • DEBATE: Early vs Delayed HCT in Myeloma
    Early HCT in Myeloma
    Natalie S Callander, MD  |  University of Wisconsin, Madison, Wisconsin, USA
    Late HCT in Myeloma
    Clifton C Mo, MD  |  Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • DEBATE: Should Patients with AML and Active Disease be Transplanted?
    PRO 
    Boglarka Gyurkocza, MD   |  Memorial Sloan Kettering, New York, New York, USA
    CON
    Edmund K Waller, MD, PhD, FACP  |  Winship Cancer Institute, Atlanta, Georgia, USA
  • Oral Abstract  |  CT
    TBA
8:00 AM–
9:22 AM
Session XIV: Next Questions
Chairs: Jennifer Brown & Guillermo Garcia-Manero
  • Next Questions: Acute Lymphoblastic Leukemia
    Elias Jabbour, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Next Questions: Acute Myeloid Leukemia
    Farhad Ravandi, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Next Questions: Cellular Therapy
    Marcos de Lima, MD  |  Ohio State University, Columbus, Ohio, USA
  • Next Questions: Chronic Lymphocytic Leukemia
    Nitin Jain, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Next Questions: Chronic Myeloid Leukemia
    Philippe Rousselot, MD, PhD  |  Mignot University de Versailles, Saint-Quentin-en-Yvelines, Paris, France
  • Next Questions: Aggressive B-Cell Lymphoma
    Grzegorz S Nowakowski, MD   |  Mayo Clinic Rochester, Rochester, Minnesota, USA
  • Next Questions: Indolent B-Cell Lymphoma
    Loretta Nastoupil, MD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Next Questions: T-Cell Lymphoma
    Matthew A Lunning, DO  |  University of Nebraska, Omaha, Nebraska, USA
  • Next Questions: Mantle Cell Lymphoma
    Andre Goy, MD, MS  |  Hackensack University, Hackensack, New Jersey, USA
  • Next Questions: Hodgkin Lymphoma
    Alex Herrera, MD  |  City of Hope Cancer Center, Duarte, California, USA
  • Next Questions: Multiple Myeloma
    Robert Z Orlowski, MD, PhD  |  MD Anderson Cancer Center, Houston, Texas, USA
  • Next Questions: Myelodysplastic Neoplasms
    Guillermo Garcia-Manero, MD  |  MMD Anderson Cancer Center, Houston, Texas, USA
  • Next Questions: Myeloproliferative Neoplasms
    John Mascarenhas, MD  |  Mount Sinai Hospital, New York, New York, USA
9:52 AM–
12:02 PM
SOHO 2023: Closing Session
  • Closing Remarks
    Jennifer R Brown, MD, PhD  |  President, Society of Hematologic Oncology
    and, Director, Chronic Lymphocytic Leukemia (CLL) Center Institute Physician Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology, Harvard Medical School
  • SOHO 2023 Drawing
  • Adjourn
12:02 PM–
12:17 PM